• Data should be released when the regulatory review is completed. There is no reason to keep confidential the efficacy and safety data of drugs that are available on the market or refused to enter the market.
Mexico City (apro).-The World Health Organization (WHO) requires the pharmaceutical industry to “provide extensive access to clinical data of all new drugs and vaccines-19”, so it must have this information.
In a joint statement issued with the International Federation of Drug Regulators (ICMRA), the World Health Organization clearly stated that access to these clinical data has the following goals:
?? Support the decision-making of regulatory agencies and health authorities, support the treatment decisions of health professionals, and support the public’s confidence in the vaccines and therapies being implemented.
Another?? Benefit?? What does the statement say will provide access to this information? Is it possible to verify the integrity of the data? Therefore, such access is a scientific need. It is also a “moral obligation.”
?? The release of data makes scientific progress faster and avoids unnecessary repeated testing and waste of resources (human and financial resources). WHO and ICMRA added that this also brings benefits by improving the efficiency of development plans and reducing development costs and time.
Many ?? public institutions ?? There are many ?? They have put forward a request for open access, because the data has been regarded as a common interest. During these pandemic times.
More content: • Data must be released when the regulatory review is completed. There is no reason to keep confidential the efficacy and safety data of drugs that are available on the market or refused to enter the market.
Similarly, they recognize that there is a “small risk”-abuse? Piracy? Still through data mining for commercial purposes-but we still continue to rely on overwhelming positive benefits for public health services-to gain access to this clinical information.